Stewart RA, et al. - Using data from a clinical cohort of patients, researchers approximated sustained virologic response (SVR) after treatment with sofosbuvir-based regimens for hepatitis C virus (HCV) infections in underserved individuals. They also reviewed the frequency of SVR across published studies of underserved populations. Study participants were aged ≥ 18 years and started sofosbuvir-based regimens for HCV infection between February 2014 and June 2016 at an urban public hospital network that serves as the healthcare safety-net for Tarrant County, Texas. Researchers found that direct-acting antivirals, especially ledipasvir/sofosbuvir, were generally effective for achieving SVR among underserved patients with HCV infections. They also provided encouraging evidence for the potential reduction of persistent inequalities in HCV prevalence and poor outcomes in this vulnerable population.